TrialEuropean radiology2021

Comparing RECIST 1.1 and iRECIST in advanced melanoma patients treated with pembrolizumab in a phase II clinical trial.

Firas S Ahmed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.